Market Size (2016)
2016
$11.45B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$11.45B
Projected (2025)
2025
$15.06B
CAGR (2016–2025)
3.1%
3.1%Key Players
109+
Allergic rhinitis, also known as hay fever, is an allergic disease associated with the nose. The allergic rhinitis affects when the immune system of the human body becomes sensitized and overreacts to specific allergens in the environment which are generally not harmful to most of the people. Allergic rhinitis can be categorized as three different types viz., seasonal, perennial, and occupational.
Key Contributing Factors
There are numerous factors that contribute to the growth of the allergic rhinitis market. The key factors are mentioned below in brief.
Rising Prevalence of Allergic Rhinitis
According to the American Academy of Asthma & Immunology, allergic rhinitis affects 10% to 30 % of the global population. Additionally, National Center for Biotechnology Information (NCBI) reported that the prevalence of allergic rhinitis in the US is approximately 15% based on the physician’s diagnosis and as high as 30% on the basis of self-reported nasal symptoms.
Government Initiatives to Create Awareness
International organizations are creating awareness in order to address diagnosis, management, prevention, and awareness of chronic obstructive lung disease. For instance, Allergic Rhinitis and its Impact on Asthma (ARIA), has collaborated with the World Health Organization (WHO), to educate and implement evidence-based management for allergic rhinitis and asthma worldwide.
Increasing Healthcare Expenditure
Respiratory disease is a huge burden on society in terms of disability and premature mortality, and also indirect health service costs, drugs prescribed, and the indirect costs related to lost production. For instance, according to a survey by the NCBI, the average per-patient expenditure for prescription medication was USD 657 yearly.
The Allergic Rhinitis Market market is projected to grow at a CAGR of 3.1% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAllergic rhinitis is caused due to sensitization of the immune system in response to allergens, which are generally harmless for most individuals. The sensitization results in the overreaction of the immune system causing inflammation of nose, congestion, sinus pressure, and sneezing, among other symptoms.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansBargaining Power of Suppliers
The bargaining power of suppliers in the allergic rhinitis market is moderate. The number of suppliers in the market is sufficiently high to provide plenty of options to drug manufacturers for material sourcing which is required for the production of the various drugs, thus leaving suppliers with moderate bargaining power. Another factor affecting the bargaining power of suppliers is the supplier switching cost for buyers owing to the presence of a moderate number of raw material suppliers in the market. On the other hand, only a moderate number of viable raw material substitutes are available, which further boosts the bargaining power of suppliers in the market.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global allergic rhinitis market. The market has a moderate number of buyers for various allergic rhinitis treatment drugs. The buyers of allergic rhinitis treatment in the global market are highly inclined towards brand identity. Moreover, the buyers can exert moderate to high pressure on the drugs manufacturing companies as some of the companies provide their product at a high cost. Hence, due to the presence of a large number of companies and a huge number of products, the bargaining power of buyers tends to be moderate.
Threat of New Entrants
The threat of new entrants is moderate to high in the global allergic rhinitis market. Prevalence of allergic rhinitis is increasing significantly, which has increased the demand for new drugs. Moreover, increasing geriatric population and funding is influencing many of the start-ups to take a keen interest in the field of research & development. Introduction of new drugs requires a long-time clinical trial and a huge capital. This is the reason that there are moderate to high possibilities for new entrants in the market.
Threat of Substitutes
The threat of substitutes in the global allergic rhinitis market is low. There are a very few substitute treatment methods which pose a low threat in the global allergic rhinitis market.
Intensity of Rivalry
The degree of competition in the global allergic rhinitis market is moderate to high. People are more inclined to brand identity. However, increasing government support and the availability of funding has encouraged many new start-ups. To compete with multinational players, new and small companies are reducing the cost of their products, which makes the intensity of rivalry moderate to high.
Market estimates by geography (2025)
InsightEurope leads with $5.19B by 2025, while Asia Pacific is projected to grow fastest at a 3.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $818.78M | $954.04M | $1.08B | 3.1% | 7% |
| Americas | $4.11B | $4.63B | $5.10B | 2.4% | 34% |
| Asia Pacific | $2.68B | $3.21B | $3.70B | 3.6% | 25% |
| Europe | $3.84B | $4.54B | $5.19B | 3.4% | 34% |
| Total | $11.45B | $13.33B | $15.06B | 3.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$14.04B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Seasonal Allergic Rhinitis | $7.67B | 3.1% | 78% |
| Perennial Allergic Rhinitis | $5.37B | 3.1% | 87% |
| Occupational Allergic Rhinitis | $1.00B | 3.1% | 89% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Allergic Rhinitis Market covering market dynamics, competitive landscape, and strategic outlook.
The Allergic Rhinitis Market market is projected to reach $15.06B by 2025, growing at 3.1% CAGR. The Seasonal Allergic Rhinitis segment holds the largest share.
Allergic rhinitis also known as hay fever is a type of inflammation which occurs due to the allergic response to specific allergens in the air. Allergic rhinitis treatment includes medications such as corticosteroids, antihistamines, nasal sprays, and leukotriene modifier.
The global allergic rhinitis market is emerging due to the increasing prevalence of allergic rhinitis, increasing government initiatives to promote awareness regarding allergic rhinitis, and growing healthcare expenditure and expansion of the private healthcare system.
However, the complications and side effects arising from allergic rhinitis medications and patent expiry are hampering the growth of the market.
Likewise, increasing demand in developing countries and exploring advanced products are likely to pose as an opportunity for the allergic rhinitis market.
Allergic rhinitis is an inflammation of the nose caused by inhaling allergens such as pollen or dust. The allergic rhinitis market is witnessing considerable growth due to the rising prevalence of hay fever among the population. For instance, according to the American Academy of Asthma & Immunology, allergic rhinitis affects 10% to 30 % of the global population. Additionally, National Center for Biotechnology Information (NCBI) reported that the prevalence of allergic rhinitis in the US is approximately 15% based on the physician’s diagnosis and as high as 30% on the basis of self-reported nasal symptoms.
Furthermore, the European Academy of Allergy and Clinical Immunology (EAACI), stated that over 150 million Europeans suffer from chronic allergic disease, out of which 100 million Europeans suffer from allergic rhinitis. Additionally, the NCBI stated that the prevalence of allergic rhinitis has increased in high-income countries, due to a significant rise in air pollutants.
The increasing number of patients affected with allergic rhinitis across the globe is driving the growth of the allergic rhinitis market.
Developing countries with a large population and recent developments provide a great opportunity for the companies and for device manufacturers to flourish in the market. The developing infrastructure and healthcare expenditure in Africa, India, and other countries provide large opportunities to allergic rhinitis market companies. These countries and the rapid advancements of technology are expected to record higher cases of asthma and COPDs which are currently undiagnosed. These developing countries are likely to witness a growth in the per capita disposable incomes which will eventually increase the affordability for these people for the treatment.
Allergic rhinitis market is facing a major threat in the form of patent expiry which is likely to hamper the market in the near future. Major market players and their drugs are either losing patent or are undergoing lawsuits regarding retaining their patency. For instance, Avamys/Veramyst nasal spray by GlaxoSmithKline is a corticosteroid treatment indicated for the treatment of symptoms of seasonal and perennial allergic rhinitis in adults and children above two years. This drug is likely to lose its patent in 2021 in the US, and in 2023 in the European Union (EU).
Apotex sought permission from the Food and Drug Administration (FDA) to manufacture the generic version of Dymista nasal spray before the patent expiry. However, generic drug maker Cipla Ltd and its American partner Meda Pharmaceuticals Inc. have jointly sued the Apotex group in the US to defend patent rights for its Dymista nasal spray, which is used to treat seasonal allergic rhinitis.
This lawsuit and patent expiry are hampering the growth of the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Allergic Rhinitis Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Meda Pharmaceuticals
Company Headquarters: Dubai, UAE Founded: 1954 Workforce: ~4,600 Company Working: Meda Pharmaceuticals operates as a subsidiary of Mylan NV and is actively involved in the production, distribution, and marketing of prescription and OTC pharmaceutical products. The company operates through the following business segments— allergy, pain management, gastrointestinal, urology, cardio and CNS, dermatology, and OTC. It has a direct presence in 60 countries and it also offers its products through distributors in more than 150 countries including Australia, China, Italy, South Africa, the UK, and the UAE. More than 50% of its revenue comes from respiratory, dermatology, and pain and inflammation therapeutic areas
ALK-Abelló A/S
Company Headquarters: Hoersholm, Denmark Founded: 1923 Workforce: ~2,379 Company Working: ALK-Abelló A/S is one of the major players in the global allergic rhinitis market. The company focuses on manufacturing, distribution, and marketing of products which are used for presentation and treatment of allergies. The company operates through three segments, namely SCIT & SLIT-drops, SCIT & SLIT-drops, and others. The company offers healthcare products in the form of tablets and drops. Moreover, ALK-Abelló A/S provides its products in major markets such as North America and Europe and is directly present in more than 38 international markets including Denmark, Austria, France, Germany, US, Canada, and China.
AstraZeneca
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
Boehringer Ingelheim International GmbH
Company Headquarters: Ingelheim am Rhein, Germany Founded: 1885 Workforce: ~50,370 Company Working: Boehringer Ingelheim International GmbH (Boehringer Ingelheim) has more than 100 years of legacy. Boehringer Ingelheim has three main business units, which include prescription medicine, animal health, and biopharma. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself. Geographically it has its presence in Africa, Asia, Australasia, Europe, North America, and South America.
Johnson & Johnson Services Inc.
Company Headquarters: New Jersey, US Founded: 1886 Workforce: ~130,000 Company Working: Ethicon, Inc. is a subsidiary of Johnson & Johnson. It was incorporated as a separate company under the Johnson & Johnson umbrella in 1949 to expand and diversify the Johnson & Johnson product line. Ethicon has manufactured surgical sutures and wound closure devices since 1887. Ethicon manufactures sutures, endocutters, breast care products, and energy-based products, like hand instruments, for tissue dissection. In 2016, Ethicon acquired NeuWave Medical, Inc.Johnson & Johnson is the world’s largest and broadly based healthcare company. It engages in the R&D, manufacture, and sale of products in the healthcare field. I Its pharmaceutical segment is focused on six therapeutic areas, including immunology, infectious diseases, oncology, cardiovascular and metabolism, and pulmonary hypertension t has more than 130 years of industry experience. The company has a team of 134,000 people at 260 companies in more than 60 countries around the globe.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Allergic Rhinitis Market